Literature DB >> 30594916

The altered expression levels of miR-186, miR-494 and miR-3651 in OSCC tissue vary from those of the whole blood of OSCC patients.

Jutta Ries1, Christoph Baran1, Falk Wehrhan1, Manuel Weber1, Constantin Motel2, Marco Kesting1, Emeka Nkenke3.   

Abstract

BACKGROUND: Altered expressions of miR-186, miR-494 and miR-3651 in whole blood of OSCC patients have already been demonstrated. However, nothing is known about their expression in tumor tissues. This study aimed at evaluating differences in miRNA expression in OSCC tissues compared to healthy oral mucosa and at checking if the altered expression is reflected in corresponding blood.
METHODS: In 53 OSCC and 40 healthy mucosal tissues the expression of miR-186, -494 and -3651 was determined by RT-qPCR and expression levels were compared between the groups. The altered expression in tissues was compared with that determined for corresponding blood. MiR-3651 target genes were identified using TargetScan software.
RESULTS: Differential expression of miR-186 and miR-494 could not be observed in tumor tissues compared to normal mucosa (pmiR-186= 0.13; pmiR-494= 0.35). Contrary to the detected upregulation of the miR-3651 in the blood of OSCC patients, a significant downregulation was observed in OSCC tissues. A significant correlation between underexpression and diagnosis was ascertained (p= 0.0001). 1710 possible target genes of miR-3651 were identified.
CONCLUSIONS: Decreased expression of miR-3651 in OSCC tissues may be a diagnostic biomarker. The opposite change in expression level in the blood might indicate different functions of this miRNA in circulation and tissue.

Entities:  

Keywords:  Oral squamous cell carcinoma; RT-qPCR; miRNA expression; tumor tissue; whole peripheral blood

Mesh:

Substances:

Year:  2019        PMID: 30594916     DOI: 10.3233/CBM-180032

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

1.  Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.

Authors:  Barbara Zellinger; Ulrich Bodenhofer; Immanuela A Engländer; Cornelia Kronberger; Brane Grambozov; Elvis Ruznic; Markus Stana; Josef Karner; Gerd Fastner; Karl Sotlar; Felix Sedlmayer; Franz Zehentmayr
Journal:  Breast Cancer       Date:  2021-12-05       Impact factor: 4.239

Review 2.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

3.  miR-3651 Participates in the Growth Cycle of Hepatocellular Carcinoma Cells and Promotes the Malignant Metastasis via the PI3K/AKT/mTOR Signalling Pathway.

Authors:  Yawei Liu; Litian Hu; Qinqiang Liu; Jing Ye; Jianping Zhang
Journal:  J Oncol       Date:  2022-09-19       Impact factor: 4.501

Review 4.  Functional Landscape of Dysregulated MicroRNAs in Oral Squamous Cell Carcinoma: Clinical Implications.

Authors:  Ruma Dey Ghosh; Arun Pattatheyil; Susanta Roychoudhury
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

5.  Serum miR-191 and miR-425 as Diagnostic and Prognostic Markers of Advanced Gastric Cancer Can Predict the Sensitivity of FOLFOX Chemotherapy Regimen.

Authors:  Liang-Yu Bie; Ning Li; Wen-Ying Deng; Xiao-Yu Lu; Ping Guo; Su-Xia Luo
Journal:  Onco Targets Ther       Date:  2020-02-25       Impact factor: 4.147

6.  MicroRNA-31 Regulates Expression of Wntless in Both Drosophila melanogaster and Human Oral Cancer Cells.

Authors:  Ji Eun Jung; Joo Young Lee; In Ryoung Kim; Sang Mee Park; Ji Wan Kang; Yun Hak Kim; Hae Ryoun Park; Ji Hye Lee
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.